Ultrasound-Mediated Drug Delivery

AuthorsStephen Sonis
PublishedJune 09, 2016
JournalOral Diseases


For patients with ulcerative colitis, the most common form of inflammatory bowel disease (IBD), aminosalicylates such as mesalamine provide first-line anti-inflammatory therapy.  As efficacy is related to tissue concentration, when administered as a rectal enema, lack of retention challenges topical formulation effectiveness.  To address this problem, Schoellhammer and his colleagues (Wu et al, 2015) recently described the development and pre-clinical testing of a novel delivery system in which they incorporated low-frequency ultrasound (LFU) as a means to enhance transmucosal drug delivery through the gastrointestinal mucosa.

Read full publication